Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of BL-M07D1 + pertuzumab + trastuzumab versus pertuzumab + docetaxel in first-line HER2-positive recurrent or metastatic breast cancer
CTR20261277Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Apr 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of BL-M07D1, pertuzumab, trastuzumab, docetaxel in breast cancer, sponsored by Biokin Pharmaceutical. Started Apr 2026; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20261277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261277.